Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study

Imagem de Miniatura
Arquivos
art_IBRAHIM_Rapid_antidepressant_changes_with_sleep_deprivation_in_major_2011.PDF (310.98 KB)
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
IBRAHIM, Lobna
DUNCAN, Wallace
LUCKENBAUGH, David A.
YUAN, Peixiong
ZARATE JR., Carlos A.
Citação
BRAIN RESEARCH BULLETIN, v.86, n.1-2, p.129-133, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
While conventional antidepressants benefit many patients with major depressive disorder (MDD), as much as eight to 12 weeks can elapse before significant improvements in depressive symptoms are seen. Treatments that act more rapidly in MDD are urgently needed. Sleep deprivation (SD) has been shown to produce a rapid antidepressant response within one day in 50-60% of patients with MDD; thus, identifying its antidepressant mechanism may contribute to the development of antidepressants that act more rapidly. The present study evaluated the effects of 39 h of SD on mood, as well as on plasma levels of brain derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) in patients with MDD. After a drug-free period of at least two weeks, 11 patients (6 males, 5 females; ages 25-62) who met DSM-IV criteria for MDD underwent total SD. Plasma samples for BDNF and VEGF assays were collected on Days 1 (baseline) and 2. The six-item Hamilton Rating Scale for Depression (HAMD-6) was the primary outcome measure. HAMD-6 scores decreased significantly after SD (Day 2). SD was negatively correlated with change in HAMD-6 score and change in VEGF levels, indicating that as depression scores decreased following SD, VEGF plasma levels increased. In contrast, SD did not alter plasma BDNF concentrations, nor was an association found between BDNF levels and clinical improvement on the HAMD-6. These results suggest that SD is associated with mood-related changes in plasma VEGF levels, but not plasma BDNF levels. Further studies using larger sample sizes are needed to confirm these preliminary findings.
Palavras-chave
Antidepressant, Depression, Neurotrophic factors, Sleep deprivation
URI
https://observatorio.fm.usp.br/handle/OPI/24101
Referências
  1. AITKEN RCB, 1969, P ROY SOC MED, V62, P989
  2. Machado-Vieira R, 2009, J CLIN PSYCHIAT, V70, P1662, DOI 10.4088/JCP.08m04659
  3. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  4. Malberg JE, 2000, J NEUROSCI, V20, P9104
  5. Viikki M, 2010, NEUROSCI LETT, V477, P105, DOI 10.1016/j.neulet.2010.04.039
  6. Altar CA, 2004, J NEUROSCI, V24, P2667, DOI 10.1523/JNEUROSCI.5377-03.2004
  7. Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905
  8. Lee BH, 2010, PSYCHIAT INVEST, V7, P231, DOI 10.4306/pi.2010.7.4.231
  9. Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013
  10. Monteggia LM, 2004, P NATL ACAD SCI USA, V101, P10827, DOI 10.1073/pnas.0402141101
  11. Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005
  12. Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1
  13. Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5
  14. Claassen CA, 2007, J AFFECT DISORDERS, V97, P77, DOI 10.1016/j.jad.2006.05.026
  15. Greene J, 2009, NEUROPSYCHOPHARMACOL, V34, P2459, DOI 10.1038/npp.2009.68
  16. Gorgulu Y, 2009, BRAIN RES BULL, V80, P158, DOI 10.1016/j.brainresbull.2009.06.016
  17. Cirelli C, 2000, BRAIN RES, V885, P303, DOI 10.1016/S0006-8993(00)03008-0
  18. Ventriglia M, 2009, PROG NEURO-PSYCHOPH, V33, P146, DOI 10.1016/j.pnpbp.2008.11.009
  19. Newton SS, 2003, J NEUROSCI, V23, P10841
  20. HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x
  21. Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7
  22. Hoshaw BA, 2005, BRAIN RES, V1037, P204, DOI 10.1016/j.brainres.2005.01.007
  23. Iga J, 2007, PROG NEURO-PSYCHOPH, V31, P658, DOI 10.1016/j.pnpbp.2006.12.011
  24. WU JC, 1990, AM J PSYCHIAT, V147, P14
  25. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  26. Teixeira AL, 2010, BIOMARK MED, V4, P871, DOI [10.2217/bmm.10.111, 10.2217/BMM.10.111]
  27. Fernandes B, 2009, NEUROSCI LETT, V453, P195, DOI 10.1016/j.neulet.2009.02.032
  28. Birnbaum HG, 2010, DEPRESS ANXIETY, V27, P78, DOI 10.1002/da.20580
  29. Bocchio-Chiavetto L, 2006, EUR NEUROPSYCHOPHARM, V16, P620, DOI 10.1016/j.euroneuro.2006.04.010
  30. First M. B., 2002, STRUCTURED CLIN INTE
  31. Manji HK, 2002, MOL PSYCHIATR, V7, pS1, DOI 10.1038/sj.mp.4001068
  32. Tadic A, 2010, PROG NEUROPSYCHOPHAR
  33. Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104
  34. WIRZJUSTICE A, 1981, PSYCHIAT RES, V5, P67, DOI 10.1016/0165-1781(81)90062-7
  35. Zucconi GG, 2006, BRAIN RES BULL, V69, P375, DOI 10.1016/j.brainresbull.2006.01.009

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27